TD Waterhouse Canada’s Acurx Pharmaceuticals ACXP Stock Holding History

TD Waterhouse Canada’s Portfolio ACXP Stock Details ACXP Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q1	–	Sell	-933	Closed	-$14.9K	–	1950
2024 Q4	$14.9K	Hold	933	–	–	﹤0.01%	1337
2024 Q3	$35.6K	Hold	933	–	–	﹤0.01%	1121
2024 Q2	$39.9K	Hold	933	–	–	﹤0.01%	1072
2024 Q1	$39.9K	Hold	933	–	–	﹤0.01%	1101
2023 Q4	$73.5K	Hold	933	–	–	﹤0.01%	872
2023 Q3	$25.7K	Hold	933	–	–	﹤0.01%	1056
2023 Q2	$49.4K	Hold	933	–	–	﹤0.01%	932
2023 Q1	$63.4K	Hold	933	–	–	﹤0.01%	860
2022 Q4	$77.4K	Sell	933 -567	-38%	-$37.3K	﹤0.01%	811
2022 Q3	$90.9K	Hold	1,500	–	–	﹤0.01%	788
2022 Q2	$110K	Hold	1,500	–	–	﹤0.01%	783
2022 Q1	$102K	Hold	1,500	–	–	﹤0.01%	841
2021 Q4	$138K	Buy	+1,500	New	+$143K	﹤0.01%	818

Other funds holding ACXP

Sabby Management Miami Beach, Florida $45.1M AUM 74.25% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

PFS

Prospect Financial Services Melville, New York $164M AUM 19.24% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

VCWA

Vanguard Capital Wealth Advisors Denver, Colorado $148M AUM 91.21% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

NBC Securities Birmingham, Alabama $1.48B AUM 31.07% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

TD Waterhouse Canada's ACXP Position: Q1 2025 in Review

TD Waterhouse Canada sold out of Acurx Pharmaceuticals (ACXP) in Q1 2025, closing a stake of 933 shares — an estimated $14.9K sold.

TD Waterhouse Canada first reported a position in ACXP in Q4 2021 and held it in 13 quarters. The position peaked at $138K in Q4 2021. 24 funds tracked by Wall St. Rank hold ACXP as of Q1 2025.

TD Waterhouse Canada reported no remaining Acurx Pharmaceuticals position as of Q1 2025 after selling out during the quarter.
TD Waterhouse Canada sold 933 Acurx Pharmaceuticals shares in Q1 2025, an estimated $14.9K.
TD Waterhouse Canada first reported a position in Acurx Pharmaceuticals in Q4 2021 and held it in 13 quarters.
TD Waterhouse Canada's Acurx Pharmaceuticals position peaked at $138K in Q4 2021.
24 funds tracked by Wall St. Rank held Acurx Pharmaceuticals as of Q1 2025.

Based on TD Waterhouse Canada's 13F filing for Q1 2025, filed 9 May 2025.